原始来源记录
决策级临床试验登记变更
Rapport Therapeutics 将 RAP-219 Phase 3 启动提前至 Q2 2026
End-of-Phase-2 会议后的 FDA 许可允许 RAP-219 直接进入局灶性发作的注册试验。公司将 Phase 3 计划启动从 Q3 2026 提前至 Q2 2026。开放标签长期安全性扩展研究已开始从已完成的 Phase 2a 研究招募患者。
关键事实
来源摘录
EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial in bipolar mania, long-acting injectable, and other pipeline programs continuing to progress BOSTON and SAN DIEGO, January 7, 2026 (GLOBE NEWSWIRE) – Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Compa
该资产的更多信息
决策级
2026年8月5日
11:17
RAPPRapport Therapeutics值得关注
2026年5月7日
11:15
RAPPRapport TherapeuticsRapport Therapeutics 将 RAP-219 双相躁狂 II 期主要数据提前至 2026 年第四季度